At the time of writing there are some new lipid-lowering drugs on the market, but attempts to influence atherosclerosis by new mechanisms have unfortunately generally been unsuccessful so far. This article briefly reviews selected developments that may be of interest to the non-specialist practitioner.
Byline: Sheibaninia A, Valaiee N, Bita Tavakoli, Azizi F, Mohamadsadeghi Sh and Nourbakhsh M – Email: [email protected] ABSTRACT
The myelodysplastic syndromes (MDSs) are clonal bone marrow (BM) disorders characterized by ineffective hematopoiesis, a variable degree of cytopenia, and an increased risk for developing acute leukemia. (1) They are often viewed as diseases of adults, particularly the elderly. The term pediatric preleukemic syndrome appeared in the literature in the early 1970s. (2) By 1980, […]